BiotechTube
AusperBio

AusperBio

Cambridge, United States· Est.
ausperbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $180M

Overview

AusperBio is a private, pre-revenue biotech founded in 2019, advancing a novel Antisense Oligonucleotide (ASO) platform called Med-Oligo™. The company's lead program is in Phase II trials for HBV, targeting a functional cure, a significant unmet medical need. By combining its platform with targeted delivery technologies, AusperBio aims to expand into other therapeutic areas beyond virology. Its success hinges on clinical validation of its platform and its ability to secure partnerships or further funding to advance its pipeline.

OncologyInfectious DiseaseMetabolic DiseaseGenetic DisordersImmune Diseases

Technology Platform

Proprietary Med-Oligo™ ASO (Antisense Oligonucleotide) platform integrated with targeted delivery technologies for enhanced stability, potency, and tissue-specific targeting.

Funding History

4
Total raised:$180M
Series B$50M
PIPE$73M
Series A$45M
Seed$12M

Opportunities

The global market for an HBV functional cure is multi-billion dollar and represents a major unmet need.
Success in HBV validates the Med-Oligo™ platform, creating significant opportunities to expand into other large therapeutic areas like metabolic and genetic diseases.
The growing acceptance and commercial success of oligonucleotide therapeutics provide a favorable market environment.

Risk Factors

High risk of clinical failure in the lead Phase II HBV program, which could devalue the platform.
Intense competition from other biotechs and pharma companies pursuing HBV cures with different modalities.
Dependence on raising additional capital in a competitive financing environment to advance the pipeline.

Competitive Landscape

AusperBio competes in the crowded HBV curative space against companies like Gilead, Janssen, Arbutus Biopharma, and others using siRNA (e.g., Vir Biotechnology/Alnylam), capsid inhibitors, and immunotherapies. In the broader ASO field, it competes with established players like Ionis Pharmaceuticals and Biogen, as well as numerous biotech startups, necessitating clear differentiation in efficacy, delivery, or safety.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →